Logo image of CMD

Cantel Medical (CMD) Stock Fundamental Analysis

USA - NYSEARCA:CMD -

80.37
-0.96 (-1.18%)
Last: 6/1/2021, 8:24:59 PM
80.37
0 (0%)
After Hours: 6/1/2021, 8:24:59 PM
Fundamental Rating

3

Overall CMD gets a fundamental rating of 3 out of 10. We evaluated CMD against 189 industry peers in the Health Care Equipment & Supplies industry. CMD has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, CMD is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year CMD was profitable.

1.2 Ratios

Industry RankSector Rank
ROA 2.56%
ROE 6.37%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Industry RankSector Rank
OM 11.54%
PM (TTM) 4.57%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

3

2. Health

2.1 Basic Checks

CMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

An Altman-Z score of 2.98 indicates that CMD is not a great score, but indicates only limited risk for bankruptcy at the moment.
CMD has a Debt/Equity ratio of 0.90. This is a neutral value indicating CMD is somewhat dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.9
Debt/FCF N/A
Altman-Z 2.98
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 2.58 indicates that CMD has no problem at all paying its short term obligations.
A Quick Ratio of 1.84 indicates that CMD should not have too much problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 2.58
Quick Ratio 1.84

6

3. Growth

3.1 Past

The earnings per share for CMD have decreased strongly by -29.96% in the last year.
Measured over the past years, CMD shows a very strong growth in Earnings Per Share. The EPS has been growing by 25.92% on average per year.
The Revenue has grown by 11.37% in the past year. This is quite good.
The Revenue has been growing by 12.45% on average over the past years. This is quite good.
EPS 1Y (TTM)-29.96%
EPS 3Y-4.57%
EPS 5Y25.92%
EPS Q2Q%27.03%
Revenue 1Y (TTM)11.37%
Revenue growth 3Y9.68%
Revenue growth 5Y12.45%
Sales Q2Q%32.51%

3.2 Future

Based on estimates for the next years, CMD will show a very strong growth in Earnings Per Share. The EPS will grow by 21.07% on average per year.
The Revenue is expected to grow by 8.80% on average over the next years. This is quite good.
EPS Next Y82.92%
EPS Next 2Y37.5%
EPS Next 3Y29.83%
EPS Next 5Y21.07%
Revenue Next Year17.48%
Revenue Next 2Y11.96%
Revenue Next 3Y10.48%
Revenue Next 5Y8.8%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CMD Yearly Revenue VS EstimatesCMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B
CMD Yearly EPS VS EstimatesCMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1 2 3 4

2

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 48.42 indicates a quite expensive valuation of CMD.
When comparing the Price/Earnings ratio of CMD to the average of the S&P500 Index (26.51), we can say CMD is valued expensively.
With a Price/Forward Earnings ratio of 25.61, CMD can be considered very expensive at the moment.
CMD is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 22.53, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 48.42
Fwd PE 25.61
CMD Price Earnings VS Forward Price EarningsCMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 19.45
CMD Per share dataCMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20 25

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as CMD's earnings are expected to grow with 29.83% in the coming years.
PEG (NY)0.58
PEG (5Y)1.87
EPS Next 2Y37.5%
EPS Next 3Y29.83%

2

5. Dividend

5.1 Amount

CMD has a yearly dividend return of 0.13%, which is pretty low.
With a Dividend Yield of 0.13, CMD pays less dividend than the S&P500 average, which is at 2.38.
Industry RankSector Rank
Dividend Yield 0.13%

5.2 History

The dividend of CMD is nicely growing with an annual growth rate of 25.79%!
CMD has paid a dividend for less than 5 years, so there is no long track record yet.
Dividend Growth(5Y)25.79%
Div Incr YearsN/A
Div Non Decr YearsN/A
CMD Yearly Dividends per shareCMD Yearly Dividends per shareYearly Dividends per share 2018 2019 2020 0.05 0.1 0.15

5.3 Sustainability

The dividend of CMD is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP0%
EPS Next 2Y37.5%
EPS Next 3Y29.83%

Cantel Medical

NYSEARCA:CMD (6/1/2021, 8:24:59 PM)

After market: 80.37 0 (0%)

80.37

-0.96 (-1.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners0.32%
Ins Owner Change0%
Market Cap3.58B
Revenue(TTM)1.14B
Net Income(TTM)52.07M
Analysts65
Price Target63.24 (-21.31%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.13%
Yearly Dividend0.11
Dividend Growth(5Y)25.79%
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 48.42
Fwd PE 25.61
P/S 3.14
P/FCF N/A
P/OCF N/A
P/B 4.38
P/tB N/A
EV/EBITDA 19.45
EPS(TTM)1.66
EY2.07%
EPS(NY)3.14
Fwd EY3.91%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS25.57
BVpS18.36
TBVpSN/A
PEG (NY)0.58
PEG (5Y)1.87
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 2.56%
ROE 6.37%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM 11.54%
PM (TTM) 4.57%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score9
Asset Turnover0.56
Health
Industry RankSector Rank
Debt/Equity 0.9
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.58
Quick Ratio 1.84
Altman-Z 2.98
F-Score9
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-29.96%
EPS 3Y-4.57%
EPS 5Y25.92%
EPS Q2Q%27.03%
EPS Next Y82.92%
EPS Next 2Y37.5%
EPS Next 3Y29.83%
EPS Next 5Y21.07%
Revenue 1Y (TTM)11.37%
Revenue growth 3Y9.68%
Revenue growth 5Y12.45%
Sales Q2Q%32.51%
Revenue Next Year17.48%
Revenue Next 2Y11.96%
Revenue Next 3Y10.48%
Revenue Next 5Y8.8%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

Cantel Medical / CMD FAQ

What is the fundamental rating for CMD stock?

ChartMill assigns a fundamental rating of 5 / 10 to CMD.


What is the valuation status of Cantel Medical (CMD) stock?

ChartMill assigns a valuation rating of 4 / 10 to Cantel Medical (CMD). This can be considered as Fairly Valued.


How profitable is Cantel Medical (CMD) stock?

Cantel Medical (CMD) has a profitability rating of 6 / 10.


What are the PE and PB ratios of Cantel Medical (CMD) stock?

The Price/Earnings (PE) ratio for Cantel Medical (CMD) is 48.42 and the Price/Book (PB) ratio is 4.38.


What is the expected EPS growth for Cantel Medical (CMD) stock?

The Earnings per Share (EPS) of Cantel Medical (CMD) is expected to grow by 82.92% in the next year.